


Impact of Alpha-Adrenergic Receptor Antagonists on outcomes in patients with heart failure. A post-hoc analysis using National Health Fund database.

Bartosz Symonides, Jacek Lewandowski, Andrzej Śliwczyński


Supplemental Fig. S1

Primary (a) and secondary (b) endpoints in men only subgroup.



no AA	21645	17830	15360	13318	11385	8836
-------	-------	-------	-------	-------	-------	------

AA	1906	1637	1427	1252	1082	817
----	------	------	------	------	------	-----





no AA	21645	16442	13057	10501	8786	6893
-------	-------	-------	-------	-------	------	------

AA	1906	1526	1253	1003	841	641
----	------	------	------	------	-----	-----

AA - alpha-adrenolytics

Supplemental Fig. S2

Cox analysis for primary (a) and secondary (b) endpoints in men only subgroup.



AA - alpha-adrenolytics; RASI - renin angiotensin system inhibitors (converting enzyme inhibitor and/or angiotensin receptor blocker); MRA - aldosterone receptor antagonists; CCB - dihydropyridine calcium channel blockers.